


Advancing patient-centred access to medicines in partnership with healthcare systems

EMA's core recommendations

Human Stakeholders Workshop

Presented by Michael Berntgen on 24 October 2018 Head of Department, Product Development Scientific Support





Summary

Contribute to **HTAs' preparedness** and downstream decision-making for innovative medicines

Bridge from evaluation to access through collaboration with **Payers**

Reinforce **patient relevance** in evidence generation Promote use of high quality **real world data** in decision-making Develop network competencies and specialist collaborations to engage with **big data**

Deliver real-time electronic Product Information (ePI) Promote availability and the uptake of biosimilars in healthcare systems Further develop external communications to promote trust and confidence in the EU regulatory system



Contribute to HTAs' preparedness and downstream decisionmaking for innovative medicines



Ensure the evidence needed by HTAs and payers are incorporated early in drug development plans



Discuss with HTAs guidance and methodologies for


from benefit-risk to relative effectiveness assessment

evidence generation and review



Contribute to the identification of priorities for HTA

Monitor the impact of decision-maker engagement through reviews of product-specific experience





Bridge from evaluation to access through collaboration with Payers



Contribute to the preparedness of healthcare systems by creating opportunities for collaboration on horizon scanning



Enable involvement of payers' requirements in the prospective discussion of evidence generation plans



Clarify the treatment-eligible patient population included in the labelling, and its scientific rationale

\bigcirc
V

Participate in discussions clarifying the concept of unmet medical need



Reinforce patient relevance in evidence generation



Coordinate Agency's approach to patient reported outcomes (PROs). Update relevant clinical guidelines to include reference to PROs



While validating PROs, address patients' needs and leverage patients' expertise



Co-develop with EUnetHTA a core health-related quality-of-life PRO to implement in trials and to bridge the gap with comparative effectiveness assessment





Promote use of high-quality real world data (RWD) in decisionmaking



Create a sustainable, quality assured, flexible framework delivering rapid access to and analysis of representative, longitudinal RWD throughout a product's lifecycle



Develop a capacity that will enable the Agency to rapidly and securely access and analyse large amounts of healthcare data



Accelerate the implementation of a learning regulatory system based on electronic health records and other routinely collected RWD





Develop network competence and specialist collaborations to engage with big data



Implement the core recommendations emerging from the EMA/HMA Taskforce addressing areas such as harmonisation of data standards, characterisation of data quality, and provision of regulatory guidance as to acceptability of evidence



Engage proactively with new stakeholders relevant to the Big Data Landscape

	なん	Q	2
2	$\overset{\sim}{>}$	$\langle \cdot \rangle$	\searrow

Invest in capacity building across the network to acquire new skills to engage with these emerging areas



Deliver real-time electronic Product Information (ePI)



Enable real-time interactivity within the Summary of Product Characteristics and Patient Leaflet



In conjunction with Healthcare Providers and patients, develop a strategic plan to deliver ePI programme



Enable the reuse of structured medicinal product information by third parties through developing a standardised interface



7

Leverage new channels of social media communication





Promote the availability and uptake of biosimilars in healthcare systems



Further develop strategic communication campaigns to Healthcare Providers and patient organisations to reinforce trust and confidence



Enhance training of the network and non-EU regulators in the evaluation of biosimilars with extension to all therapeutic areas



Address regulatory challenges in manufacturing e.g., statistical assessment of CQAs in the comparability exercise and the evolution of multisource biologicals/biosimilars





Further develop external communications to promote trust and confidence in the EU regulatory system



^{Develop} content strategy, particularly in key public health areas and hot topics in regulatory science

- Enhance professional outreach through scientific publications & conferences
- Proactive approach to key public-health areas (e.g. vaccines)
- Improved communications for patients, HTA and payers



Develop more targeted and evidence-based communication facilitated by updated web content and format

Summary

Contribute to **HTAs' preparedness** and downstream decision-making for innovative medicines

Bridge from evaluation to access through collaboration with **Payers**

Reinforce **patient relevance** in evidence generation Promote use of high quality **real world data** in decision-making Develop network competencies and specialist collaborations to engage with **big data**

Deliver real-time electronic Product Information (ePI) Promote availability and the uptake of biosimilars in healthcare systems Further develop external communications to promote trust and confidence in the EU regulatory system





11 Advancing patient-centred access to medicines in partnership with healthcare systems